Actos Now for Prevention of Diabetes (ACT NOW)
Sponsor: Takeda Pharmaceuticals North America, Inc.
Listed as NCT00220961, this PHASE3 trial focuses on Impaired Glucose Tolerance and Type 2 Diabetes and remains completed. Sponsored by Takeda Pharmaceuticals North America, Inc., it has been updated 8 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jan 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Takeda Pharmaceuticals North America, Inc.
- The University of Texas Health Science Center at San Antonio
- University of Texas
For direct contact, visit the study record on ClinicalTrials.gov .